NY-AQARA
23.11.2022 09:01:38 CET | Business Wire | Press release
Aqara, a leading provider of smart home products, introduces its new Cube T1 Pro, which is the updated version of its iconic wireless Cube controller. Built upon the success of its predecessor, the new cube adds HomeKit and Alexa support1, so that it can be used to control a wide range of smart home devices within both ecosystems. Moreover, it adds the new Scene Mode to allow users to use not only actions but also different sides of the cube to activate smart home scenes or devices2. The Cube T1 Pro is now available on Aqara Amazon brand stores in North America (US, Canada) and Europe (France, Germany, Italy, Spain, UK), and via selective Aqara retailers worldwide.
Similar to its predecessor, the Cube T1 Pro recognizes different actions such as push, shake, rotate, flip and tap. A new Scene Mode is added, and when the mode is activated the cube also recognizes different sides, so that users can simply use each side to control various scenes and devices. Dice-like indicators are printed on the sides to help users distinguish one from the others. Moreover, thanks to this new mode the Cube T1 Pro can be used in both HomeKit and Alexa. It’s also expected to support Matter via the Aqara hubs through an OTA update, and the Hub M2 will be the first hub to receive such update.
With all these improvements, the Cube T1 Pro enables a more intuitive way to control a smart home2. For instance, users can activate the Morning Routine by flipping it to Side 1, and trigger the Home Cinema Scene by flipping it to Side 2. Additionally, it’s now possible within the Aqara Home app to control more than one sets of curtains, roller shades or lights by rotating the new cube. For example, flipping it to Side 3 and rotating the cube to adjust the open percentage of the curtains, and flipping it to Side 4 and rotating to dim the Aqara lights3. The versatility of this cube controller allows users to be creative with their smart home setups.
Based on the Zigbee 3.0 protocol which allows faster response, higher reliability, better compatibility and improved energy efficiency, the Cube T1 Pro has a battery life of up to 2 years. It also supports OTA updates, which means that new features and fixes can be added to the new cube after the its initial release.
In celebration of the launch, Aqara now offers a 10% discount for the new cube on its Amazon stores. North American customers will enjoy the offer with the promo code NACUBET1 in the US and Canada, while European customers will enjoy it using the promo code CBT1PROEU in France, Germany, Italy, Spain and the UK. Both codes can be combined with coupon, and will be valid through November 24, 2022.
For more details of the Cube T1 Pro, please visit our website.
- A Zigbee 3.0-based Aqara hub is required. The Cube T1 Pro is recognized as 6 wireless buttons in HomeKit, and as 6 motion sensors in Alexa.
- A Zigbee 3.0-based Aqara hub is required.
- The compatible Aqara lights, Curtain Driver E1 or Roller Shade Driver E1 are required.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221123005015/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom